MyoD is a transcriptional factor that is required for the differentiation of muscle stem cells (satellite cells). In this study, we describe a previously unknown function for MyoD in regulating a gene (Cdc6) that is vital to endowing chromatin with the capability of replicating DNA. In C2C12 and primary mouse myoblasts, we show that MyoD can occupy an E-box within the promoter of Cdc6 and that this association, along with E2F3a, is required for its activity. MyoD and Cdc6 are both expressed after quiescent C2C12 myoblasts or satellite cells in association with myofibers are stimulated for growth, but MyoD appears at least 2–3 h earlier than Cdc6. Finally, knockdown of MyoD impairs the ability of C2C12 cells to express Cdc6 after leaving quiescence, and as a result, they cannot fully progress into S phase. Our results define a mechanism by which MyoD helps myogenic satellite cells to enter into the first round of DNA replication after transitioning out of quiescence.
Satellite cells are self-renewing muscle stem cells, which mediate the growth and repair of skeletal muscle (Zammit et al., 2006). When the muscle is damaged, these cells leave their state of quiescence, proliferate at length to generate colonies of myoblasts, and then differentiate to form multinucleated myotubes (Zammit et al., 2006). The myogenic factor that is mainly involved in controlling the progression of these myoblasts into the differentiation state is MyoD (Le Grand and Rudnicki, 2007). This protein, which preferentially binds to a DNA consensus site (CANNTG) called an E-box, has been shown in both myogenic (C2C12) and nonmyogenic cell lines to be highly important in controlling the transcription of differentiation-specific genes (Berkes and Tapscott, 2005). This function correlates in part to the ability of MyoD to recruit histone acetyltransferases (e.g., PCAF and p300) and SWI/SNF chromatin-remodeling complexes to the promoters of these genes to affect specific changes in chromatin structure (Mal and Harter, 2003; Berkes et al., 2004). Another myogenic factor that is highly related to MyoD in both amino acid sequence and affinity to E-box sites is Myf5 (Tapscott, 2005). Mice that are null for either MyoD or Myf5 are viable, and therefore, it is widely believed that these two proteins can functionally substitute for one another during embryonic development (Le Grand and Rudnicki, 2007). However, this compensation may not be as efficient in the regeneration of muscle because cultures of MyoD−/− myoblasts, which apparently have 5–10 times more Myf5 protein, are dramatically delayed in their transition to a differentiated state (Sabourin et al., 1999; Yablonka-Reuveni et al., 1999). Moreover, these myoblasts also appear to be limited in their ability to expand in population when compared with wild type (Montarras et al., 2000), and this may reflect the fact that Myf5 is less effective than MyoD in regulating the same set of growth-phase genes (Montarras et al., 2000; Ishibashi et al., 2005).
There is evidence to suggest that MyoD may also be playing a role in helping satellite cells to expand in population upon leaving quiescence. For example, MyoD has been shown to be expressed within 3 h after the satellite cells have been activated (Jones et al., 2005). In addition, ChIP (chromatin immunoprecipitation)-on-chip analysis has shown that MyoD can target genes other than those involved in the myogenic program, and in this group were Cdc6 and MCM2. These two genes are primarily involved in making chromatin operational for DNA replication, a function which is not only essential for the proliferation of cells but also for cells emerging from quiescence (Blais et al., 2005; for review see Machida et al., 2005). MCM2 is a member of the MCM family of proteins (MCM2–7), and as a complex, these proteins along with Cdc6 and at least seven other proteins assemble at origins of DNA replication to form what is called a prereplicative complex. Studies have shown that Cdc6 is a key participant in this process because it essentially loads the MCM proteins onto the origins (for review see Machida et al., 2005). Because prereplicative complexes are largely involved in unwinding the DNA and initiating the process of replication, it is perhaps not surprising to find that the genes of many of its members, including Cdc6 and MCM2, have become temporarily silent in quiescent cells (Yan et al., 1998; Ren et al., 2002; Ghosh and Harter, 2003). Although this scenario has yet to be demonstrated in satellite cells, it is most likely that analogous mechanisms would occur, and if so, it is possible that MyoD could be involved in inducing transcription from either Cdc6 or MCM2 in these cells after leaving quiescence.
In this study, we have used mouse primary myoblasts (wild type or MyoD−/−), isolated myofibers with associated satellite cells, and the satellite-derived C2C12 cell line to investigate whether MyoD can possibly regulate genes that are an integral part of the replication system. Through biochemistry and RNAi experiments, we have uncovered a mechanism that involves MyoD in initiating the expression of Cdc6 in growth-stimulated quiescent myoblasts and shown that this induction is essential for effectively moving these cells into S phase. Furthermore, the importance of MyoD’s activity in this context is underscored by Myf5’s ability to perform this function in the absence of MyoD, although with less efficiency. Thus, our results have established a new and unexpected role for MyoD, and by all accounts, one that may be important to satellite cells as they transition out of quiescence.
Analysis of promoters for potential E-box sites
To identify potential MyoD-binding sites in the regulatory regions of genes that have been identified in inducing DNA replication, we used TRANSFAC (version 7.0, cut off 85), a database which models factor-site interactions on the sequences of DNA (Matys et al., 2006). With this computer-assisted analysis, we were able to identify within the promoters of Cdc6 and MCM2 and -7 a consensus DNA site known as an E-box for the binding of MyoD (Fig. S1 A and not depicted). The Cdc6 promoter, the one we chose to focus on, was found to contain two of these sites, with one (E1) being in close proximity to the transcriptional start site (+1) and the other (E2) much further upstream (Fig. 1 A). The position of the start site within this promoter corresponds to the 5′ terminus of an mRNA (Materials and methods) that is predicted to encode a protein of ∼62 kD, and in fact, a protein matching this size can be observed in extracts of proliferating C2C12 myoblasts, as judged by Western blot analysis (Fig. S1 B). The regulatory region of Cdc6 also contains two potential E2F-binding sites close to the transcription start site, and interestingly, one of them is located 10 bp upstream from the E1 E-box (Fig. 1 A). The arrangement of these two E2F elements is quite similar to that found in the human Cdc6 promoter (Williams et al., 1997), and it has been reported that the one nearest to the start site is mainly involved in stimulating its activity in nonmuscle cells (Schlisio et al., 2002).
Both MyoD and E2F can occupy the promoter of Cdc6 in myoblasts
We used the myogenic cell line C2C12 and mouse primary myoblasts to determine by ChIP whether any of the E-boxes within the endogenous Cdc6 promoter were capable of associating with MyoD. After immunoprecipitating cross-linked DNA fragments of ∼100–400 bp with antibodies specific for MyoD, we found that MyoD could associate with this promoter in both of these cellular environments but only near the E1 site (Fig. 1 B). The interaction of MyoD with this promoter was not the result of a promiscuous interaction because it was also able to occupy the downstream and upstream regulatory regions of MCM2 and -7, respectively (Fig. S1 C and not depicted; Juven-Gershon et al., 2008). ChIP assays in combination with kinetic experiments were then used to determine whether MyoD remained bound to the Cdc6 promoter after the myoblasts were induced to differentiate. As shown in Fig. 1 (C and D), the interaction of MyoD with this promoter diminished over time as myoblasts underwent the process of differentiation. This result is significant because it indicates a requirement for MyoD in regulating the expression of Cdc6 in satellite cells, but only while the cells are in a state of proliferation.
ChIP experiments were also performed to determine whether any member of the E2F family of transcription factors (E2F1–7) might be interacting with the Cdc6 promoter in proliferating myoblasts. As shown in Fig. 2 A, E2F3a, an isoform mainly expressed in growing cells (Leone et al., 2000), was found to be the most predominant factor in association with this promoter, although a weak binding by E2F4 could also be observed. Note that the near absence of E2F4 from the Cdc6 promoter was not the result of an antibody that had lost its specificity when used in a ChIP assay (Fig. 2 C). Although the site on the promoter to which E2F3a is binding has yet to be identified, it is possible that it may be the one closest to the transcriptional start site (Fig. 1 A), as has been previously shown in the human Cdc6 promoter (Schlisio et al., 2002). We also observed in this analysis that E2F1 was noticeably absent from the Cdc6 promoter (Fig. 2 A), and again, this result is consistent with what has been previous reported for the human Cdc6 promoter (Takahashi et al., 2000; Ren et al., 2002; Schlisio et al., 2002). E2F3a has been reported to play an important role in controlling genes that are critical to the replication of DNA. In fact, the ability of cells to enter S phase after being released from a G1/S block becomes markedly diminished if E2F3a is purposely made inactive (Leone et al., 1998). Because of this and the fact that the cessation of DNA synthesis is concurrent with the differentiation of muscle cells, we examined by ChIP assays the relationship between E2F3a and the Cdc6 promoter after myoblasts were induced to differentiate. We found by temporal analysis that E2F3a could no longer be detected on the Cdc6 promoter after 24 h of differentiation (Fig. 2 B). Perhaps equally important is that this loss also corresponded to a linear increase in the association of E2F4 with this promoter (Fig. 2 C). This observation and the fact that E2F4 functions primarily as a repressor of transcription (Blais et al., 2005) may be one reason why the expression of Cdc6 is no longer seen in differentiated muscle cells, either by immunofluorescence or by RT-PCR analysis (Fig. 2 D). We note that Cdc6 is primarily located in the nucleus of proliferating myoblasts, with some evidence of it in the cytoplasm (Fig. 2 D). This phenomenon has also been observed by others (Petersen et al., 1999; Delmolino et al., 2001) presumably because Cdc6 remains chromatin bound after S phase is initiated so that it can then participate in other cellular functions such as mitotic entry (Clay-Farrace et al., 2003).
The proximal promoter of Cdc6 is responsive to MyoD, Myf5, and E2F
To determine whether the E1 site was functionally important to the activity of the Cdc6 promoter, we first assessed the response of a reporter construct (Cdc6-wt) carrying the regulatory elements of Cdc6 in a cell line (C3H10T1/2) that does not express endogenous MyoD protein (Fig. 3 A). After this vector and a vector devoid of the Cdc6 elements were separately transfected into these cells, we found that the promoter activity of Cdc6-wt was enhanced at least sixfold when compared with the empty vector (Fig. 3 B). More importantly, though, this level of activity, which may be caused by an E2F (Fig. 2 A and Fig. S1 E), increased significantly in a dose-dependent manner after the Cdc6-wt vector was cotransfected with a vector expressing increasing amounts of MyoD (pCMV-MyoD; Fig. 3 B). To verify that this effect was truly a function of MyoD, we introduced into the E1 site of the Cdc6-wt vector a two-base mutation that has been previously shown to eliminate the binding of MyoD (Fig. 3 A; Lee et al., 2001). After transfecting this mutant vector (Cdc6-E1mut) either alone or together with pCMV-MyoD into C3H10T1/2 cells, we found that the promoter activity of Cdc6-E1mut was now severely compromised when compared with that of the Cdc6-wt vector (Fig. 3 B).
Microarray analysis has established that Myf5 can regulate many of the same genes as MyoD in proliferating cells (Ishibashi et al., 2005). Therefore, we examined the potential responsiveness of the Cdc6-wt reporter to Myf5 in C3H10T1/2 cells. After Cdc6-wt was introduced into these cells along with a plasmid encoding Myf5 (pCMV-Myf5), we found that the activity of its promoter had increased substantially when compared with its activity without Myf5 (Fig. S1 F). As expected, the activity of the mutant Cdc6 promoter (Cdc6-E1mut) was dramatically diminished after it was cotransfected into these cells with pCMV-Myf5 (Fig. S1 F). It would appear then that the proximal promoter region of Cdc6 is responsive to Myf5 as well, and this may be significant in light of the observations described below (see Fig. 6).
To further investigate the relationship between MyoD and the Cdc6 promoter and, more importantly, to ensure that the aforementioned results were not associated with an overexpressed MyoD, we introduced each of the reporter constructs into C2C12 myoblasts. As shown in Fig. 3 C, the transfected Cdc6-wt reporter responded to endogenous MyoD by showing a dramatic increase in its promoter activity (an ∼50-fold increase) relative to empty vector. However, the Cdc6-E1mut construct responded by showing at least a threefold reduction in its promoter activity when compared with that of the wild-type vector (Fig. 3 C), thereby lending further support to a role for the E1 site in controlling the Cdc6 promoter. To determine whether both the E2F and E1 sites were required for precise functioning of the Cdc6 promoter, we constructed two additional vectors in which the E2F-binding site (Cdc6-mut2) or both the E2F- and E1-binding sites (Cdc6-mut1/2) were altered by mutations (Fig. 3 C). Myoblasts were then separately transfected with each of these vectors. As shown in Fig. 3 C, the promoter activity of the Cdc6 reporter holding a mutation only in the E2F-binding site was significantly reduced when compared with that of wild type. What is more important, though, is that mutations in both the E2F and E1 sites nearly abolished the activity of the Cdc6 promoter in these cells (Fig. 3 C). Overall, these experiments suggest that the proximal E1 site within the Cdc6 promoter is responsive to MyoD, and when considering the results presented in Fig. 2 A, it appears that both MyoD and E2F3a may be required to affect full transcriptional activity of the Cdc6 gene in muscle cells.
Expression of MyoD and Cdc6 after C2C12 myoblasts or primary satellite cells leave quiescence
Recent studies have identified several genes that are up-regulated as cells move out of quiescence, and of those are a class of which encodes proteins required for giving chromatin a “license” to synthesize DNA (for review see Machida et al., 2005). Cdc6 is one of those genes (Ren et al., 2002; Ghosh and Harter, 2003), and because our data indicate that MyoD can apparently affect its promoter (Figs. 1–3,23), we hypothesized that it could be involved in transcriptionally activating Cdc6 after satellite cells leave quiescence. If this were the case, by all accounts, MyoD ought to be expressed before Cdc6 in these cells. As an initial strategy for investigating this possibility, we induced C2C12 myoblasts into a state that closely mimicked the properties of a quiescent satellite cell. This conversion was accomplished by using a well-established procedure (Kitzmann et al., 1998; Spiller et al., 2002), which includes the use of a methionine-depleted DME supplemented with 1% serum (see Materials and methods). When low-density C2C12 myoblasts were cultured under these conditions for 36 h, we found that at least 95% of them were no longer synthesizing their DNA, as judged by the incorporation of BrdU (Fig. S2 A). What is more important, though, is that these cells were barely expressing MyoD (Fig. S2 B), as indicated by immunofluorescence or RT-PCR analysis. This result strongly indicated that the majority of the myoblasts were now in a nondifferentiated and quiescent stem cell state. We also examined the expression of Cdc6 in the quiescent myoblasts, and as shown in Fig. S2 B, its level of transcription was dramatically reduced as well. These data were not entirely surprising because Cdc6 was no longer required to prepare chromatin for DNA replication in these cells nor participate in checkpoint mechanisms.
Having the C2C12 myoblasts in a quiescent state enabled us to determine whether there were any kinetic differences in expression between MyoD and Cdc6 once these cells moved into G1. After the quiescent myoblasts were restimulated for growth, we found that MyoD was indeed expressed at least 2–3 h earlier than Cdc6, as judged by both Western blot and RT-PCR analysis (Fig. 4 A). In this study, the kinetics of E2F3a expression were also monitored, and the profile was found to be virtually indistinguishable from that of MyoD (Fig. S2 C). Given this result, it was next important to determine whether the temporal expression observed between MyoD and Cdc6 was also essential to growth-stimulated primary satellite cells. Therefore, quiescent satellite cells in association with myofibers isolated from the muscle of an adult mouse were stimulated with serum and then processed for immunofluorescence using antibodies against Pax7, MyoD, or Cdc6. The staining for Pax7 was performed in this case to mark both the quiescent and activated satellite cells (Buckingham, 2007). As shown in Fig. 4 B, after the satellite cells were serum stimulated and then costained for Pax7 and MyoD or Pax7 and Cdc6, we found that the expression of MyoD was occurring at least 2–3 h before the expression of Cdc6 (Fig. 4 B). We also observed in this experiment that the activated satellite cells were coexpressing MyoD and Cdc6 by at least 8 h (Fig. S2 D). Notably, these results are indistinguishable from those observed in the growth-stimulated quiescent C2C12 myoblasts (Fig. 4, A and B), and together with the data shown in Fig. 3, they strongly suggest that the expression of Cdc6 in newly activated satellite cells may be regulated by MyoD.
We also examined the status of Myf5 expression in both quiescent and serum-stimulated C2C12 myoblasts. In contrast to MyoD, we found Myf5 to be highly expressed in the quiescent myoblasts, as determined by Western blot analysis (Fig. S2 C). However, after these cells reentered the cell cycle, its expression sharply declined, but only to resume at ∼8 h into the cell cycle (Fig. S2, C and E; and not depicted). This pattern of Myf5 expression as myoblasts leave quiescence has been previously reported by others (Kitzmann et al., 1998) and models, to some extent, the activity of the Myf5 locus in both quiescent and newly activated satellite cells (Le Grand and Rudnicki, 2007).
MyoD is required for the induction of Cdc6 after myoblasts transition out of quiescence
As shown in Figs. 3 and 4, our results suggested that MyoD participates in the activation of Cdc6 after myogenic progenitors are stimulated to leave quiescence. To further investigate this possibility, we used short hairpin–mediated RNAi (shRNA) to knock down the expression of MyoD in the hope of determining what effect, if any, this would have on the induction of Cdc6 after quiescent myoblasts were returned to the cell cycle. Three shRNAs (shRNA-63, -64, and -66) were designed to specifically target the coding sequences of MyoD, and in the end, shRNA-64 and -66 were found to be the most effective in knocking down the expression of MyoD (∼85–90%) when compared with a scrambled shRNA (unpublished data). Next, lentiviral vectors expressing shRNA-64 (shMyoD-64), shRNA-66 (shMyoD-66), or the scrambled shRNA (shCntrl) were separately transduced into C2C12 myoblasts before their conversion to quiescence, and after being brought to this state, they were then stimulated with serum (growth medium [GM]) for the indicated times (Fig. 5 A). Remarkably, after performing RT-PCR analysis on myoblasts expressing shMyoD, we observed a severe reduction not only in the levels of MyoD mRNA but also in the levels of Cdc6 mRNA as well (Fig. 5 B). In contrast, quiescent myoblasts, which had been transduced in parallel with either empty vector or shCntrl, had no difficulty in expressing either one of these genes (Fig. 5 B). We also examined the protein levels of Cdc6 after the quiescent myoblasts were serum stimulated as a function of time, and as shown in Fig. 5 C, the depletion of MyoD, either by shMyoD-64 or -66, resulted in the near absence of Cdc6 protein when compared with shCntrl. As expected, the protein profiles of E2F3a and Myf5 were found to be unaffected in the MyoD-depleted myoblasts expressing shMyoD-66 (Fig. S2 E and not depicted).
Next, we performed ChIP analysis on serum-stimulated quiescent myoblasts expressing either shMyoD-66 or the scrambled shRNA to examine the occupancy of the Cdc6 promoter under conditions of MyoD ablation. Fig. 5 D clearly demonstrates that both MyoD and E2F3a were recruited to the promoter of Cdc6 after quiescent myoblasts expressing the scrambled shRNA were stimulated with serum for 6 h. In sharp contrast, we were unable to detect any significant binding of MyoD or E2F3a to the promoter of Cdc6 after the quiescent myoblasts expressing shMyoD-66 were stimulated with serum for periods of 6, 12, or 16 h (Fig. 5 E and not depicted). This result implies that E2F3a may require MyoD for its recruitment to the Cdc6 promoter after quiescent satellite cells progress into the cell cycle.
Entry of quiescent myoblasts into S phase requires MyoD
Because Cdc6 is such a key factor in preparing chromatin for DNA replication in eukaryotic systems (Borlado and Méndez, 2008), we wanted to determine whether the depletion of MyoD had any effect on the ability of growth-stimulated quiescent myoblasts to enter into S phase, as judged by BrdU incorporation. Thus, by using the strategy described in Fig. 6 A, we found that the percentage of MyoD-depleted myoblasts entering S phase after 16 h of serum stimulation was remarkably reduced when compared with myoblasts with the shCntrl vector (Fig. 6 B). Therefore, we conclude that MyoD is required for inducing Cdc6 in growth-stimulated quiescent myoblasts, and by extrapolation, this activity could signify one mechanism for preparing recently activated satellite cells to enter S phase.
Interestingly, although the percentage of control myoblasts (shCntrl) in S phase after 36 h was virtually identical to that which was seen after 16 h, the percentage of MyoD-depleted myoblasts in S phase at the 36-h time point had increased at least threefold over that which was seen at the l6-h time point (Fig. 6 B). We propose that Cdc6 may be associated with this increase, only because its expression is unpredictably observed in the MyoD-depleted quiescent myoblasts after 16 h of serum stimulation (Fig. 5 C). Given that this time point shows no evidence for the expression of MyoD but that it does for Myf5 (Fig. 5 C and Fig. S2 E), we thought that Myf5 might perhaps be responsible for contributing to the expression of Cdc6 while under these conditions. Therefore, we tested this idea by examining the Cdc6 promoter for the occupancy of Myf5 in the MyoD-depleted quiescent myoblasts after serum stimulation. In accordance with the pattern of Myf5’s expression in growth-stimulated quiescent myoblasts (Fig. S2, C and E), we were unable to detect this protein at the promoter of Cdc6 after 6 h of serum stimulation (Fig. 7 A) but did detect it after a period of 12 h (Fig. 7 B). Perhaps more striking is that Myf5 can also readily associate with the Cdc6 promoter in MyoD−/− primary myoblasts, as demonstrated by ChIP analysis (Fig. 7 C). Collectively, these results suggest but do not prove that Myf5 can act as a replacement factor for MyoD in inducing the promoter of Cdc6, but only under a given set of circumstances.
In summary, the results presented in this study reveal a new and important role for MyoD: it can participate with other transcriptional factors (e.g., E2F3a) in regulating Cdc6, a gene which is extremely important in conferring replication competency to cells that have transitioned out of quiescence (Pelizon, 2003). This surprising observation may be one reason why satellite stem cells express high levels of MyoD within hours after their activation and before muscle-specific gene products are detected (Jones et al., 2005). Indeed, our data clearly demonstrate that when MyoD is ablated in growth-stimulated quiescent myoblasts, Cdc6 is not sufficiently induced, and consequently, these cells cannot fully progress into S phase. Thus, the ability of MyoD to affect full transcription from the Cdc6 promoter, as shown herein, is a mechanism that more than likely sets the stage for S phase in early activated satellite stem cells. Moreover, our discovery that MyoD can associate with the promoters of other genes (e.g., MCM2 and -7) that are also central to the regulation of DNA leads us to suspect that this activity is associated with parallel mechanisms for promoting these cells into S phase. Finally, our evidence indicating that Myf5 can also occupy and stimulate the Cdc6 promoter is intriguing from the standpoint that this could reflect a failsafe mechanism for assuring that activated satellite cells progress into S phase under conditions of MyoD impairment. This prediction is strengthened by the fact that ∼80% of the quiescent satellite cells, which are committed for myogenesis, transcriptionally express Myf5 (Buckingham, 2007), and exactly what function this provides in this context is still unclear. Therefore, a more general understanding of the roles of both MyoD and Myf5 during the proliferative expansion of adult myogenic stem cells is important from the perspective of new therapeutic approaches for neuromuscular diseases.
Materials and methods
Single myofiber isolation and culturing
Male C57BL/6 wild-type mice of 6 wk old (The Jackson Laboratory) were used in this study and with the approval of the Institutional Animal Care and Use Committee at Case Western Reserve University. The extensor digitorum longus muscles were removed from mice after being killed by cervical dislocation (Rosenblatt et al., 1995). To minimize satellite activation, muscles were digested without shaking in a dish with 1× DME plus 0.2% collagenase type 1 for 45 min at 35°C, as previously described (Rosenblatt et al., 1995; Wozniak and Anderson, 2005; Parise et al., 2008). Individual myofibers were dissociated by trituration, washed, and then cultured in a horse serum (HyClone)–coated Petri dish (Kord-Valmark) with added DME to maintain the associated satellite cells in a quiescent state. To activate the associated satellite cells, the cultures were switched to DME and 20% FBS with 0.5% chick embryo extract (Sera Laboratories International, Ltd) and then incubated at 37°C in 5% CO2 until harvesting. At least three to four mice per time point were used.
Cell culture and quiescence
C3H10T1/2 mouse fibroblasts and 293T cells were maintained in DME supplemented with antibiotics and 10% FBS. C2C12 skeletal muscle cells (provided by N. Rosenthal, European Molecular Biology Laboratory Monterotondo, Rome, Italy) were maintained in DME supplemented with 20% FBS (GM) as previously described (Mal et al., 2000, 2001). To prepare myotubes, myoblasts were switched to differentiating medium (DM; DME, 2% heat-inactivated horse serum, and 10 µg/ml insulin), and after 12 h, 10 µM cytosine arabinoside was added for 36 h to eliminate proliferating, nondifferentiating myoblasts (Mal et al., 2000). Methods for removing myotubes from culture dishes without quiescent undifferentiated myoblasts were as previously described (Kitzmann et al., 1998). In brief, trypsin at a concentration of 0.05% was added to cultures of myotubes followed by incubation at 37°C for ∼20–30 min.
Except for minor modifications, C2C12 myoblasts were made quiescent as previously described (Kitzmann et al., 1998; Spiller et al., 2002). In brief, myoblasts were grown on tissue culture–treated polystyrene dishes (Corning) and in medium consisting of high-glucose DME (Invitrogen) supplemented with heat-inactivated 20% FBS. Upon reaching 40–50% confluency, the cells were then switched after extensive washings in warm PBS to high-glucose DME without methionine and with 1% FBS (quiescent medium) for 36 or 48 h. Quiescent myoblasts, whose confluency was ∼30–40%, were promoted into the cell cycle by changing the medium to fresh DME with 20% FBS (GM).
shRNA-mediated gene silencing
Lentiviral-based shRNA constructs (pLKO.1) expressing shRNAs targeting the sequences of nucleotides 1,061–1,081, 1,044–1,064, or 1,126–1,146 of MyoD (GenBank/EMBL/DDBJ accession no. NM_010866) were purchased from Thermo Fisher Scientific and renamed shMyoD-63, -64, and -66, respectively. A pLKO.1 construct expressing a scrambled shRNA was purchased from Addgene and served as a negative control (shCntrl). To produce lentivirus, each of the pLKO.1 constructs was cotransfected with psPAX2 and pMD2G into 293T packaging cells as previously described (Jackson et al., 2005). Supernatants derived from these cells were then used to infect C2C12 myoblasts.
Promoter sequence analysis, expression plasmids, and gene reporter assays
Putative binding sites for MyoD (E-boxes) and E2F were identified along the 1.3-kb Cdc6 promoter by analysis with the TRANSFAC (version 7.0) computer software program (Matys et al., 2006). The Cdc6 promoter fragment was generated by PCR from mouse genomic DNA, ligated into the pGL3-basic luciferase reporter vector (Promega), and then sequenced accordingly. PCR primers (forward, 5′-AGACCTGGGGCTGTCCTATT-3′; and reverse, 5′-CTGCTCAAAACTAGCCAGCA-3′) were designed to amplify 449 bp (−168, +281) of the Cdc6 promoter sequence (GenBank/EMBL/DDBJ accession no. NM_001025779), which is numbered relative to the transcription start site at +1, is described in the NCBI UniGene database (Genome View). Nucleotide substitutions were introduced into the putative E-box or E2F site of Cdc6-wt at position −28 (TGCAGCTGCT converted to TGCAGCAACT) or −48 (TTTGGCGC converted to TTTGAAGC), respectively, by using a site-directed mutagenesis kit (Agilent Technologies). Nucleotide substitutions were also introduced into both of these sites to generate a double mutant. The DNA sequences of all of these constructs were verified accordingly.
The plasmid pCSA-MyoD expressing full-length MyoD from the CMV promoter (pCSA-MyoD) has been described previously (Skapek et al., 1996), as have the CMV promoter–driven plasmids pHIT3-Myf5 and pcDNA-mE2F3a (Wu et al., 2001; Parker et al., 2006), both of which were provided by M.A. Rudnicki (Ottawa Health Research Institute, Ottawa, Ontario K1Y 4E9, Canada) and G. Leone (The Ohio State University, Columbus, OH), respectively.
Luciferase assays were carried out by using the Dual-Luciferase Reporter Assay system (Promega) according to the manufacturer’s instruction. To control for transfection efficiency, all firefly luciferase values were normalized to Renilla luciferase.
Transfections and monitoring of DNA synthesis
For reporter gene assays, cultures of C3H10T1/2 or C2C12 myoblasts were transiently transfected with plasmids using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. Primary mouse wild-type and MyoD−/− myoblasts (provided by M.A. Rudnicki) were isolated and cultured as previously described (Sabourin et al., 1999).
To monitor for DNA synthesis, a BrdU Labeling and Detection kit (Roche) was used. In brief, C2C12 myoblasts cultured in GM, DM, or quiescent medium were labeled with 10 µM BrdU for 30 min and then processed according to the manufacturer’s instructions. The secondary antibody for BrdU staining was anti–mouse Alexa Fluor 568 or 488.
Antibodies, immunoblotting, and immunofluorescence
Antibodies recognizing MyoD (C-20 and M-318), Myf5 (C-20), E2F3a (C-20), Cdc6 (180.2 and H-304), E2F4 (C-20), E2F1 (KH95), glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 6C5), and normal rabbit IgG were obtained from Santa Cruz Biotechnology, Inc. Hybridoma cells producing the anti-Pax7 mouse monoclonal antibody were provided by M.A. Rudnicki, and Alexa Fluor 594– or Alexa Fluor 488–conjugated goat anti–mouse IgG secondary antibodies for detecting primary antibodies were purchased from Invitrogen. The spectral compatibility for these two fluorophores can be seen at http://www.invitrogen.com.
Lysis of C2C12 myoblasts and conditions for immunoblot analysis were described previously (Mal et al., 2001). In brief, 20–40 µg of extracts was separated on 10% SDS-PAGE followed by transfer to polyvinylidene difluoride membranes, which were then probed with the primary antibody and, afterward, the secondary antibody followed by ECL (GE Healthcare). Immunofluorescence was performed on myoblasts or myotubes as previously described (Mal et al., 2000, 2001).
Myofibers were fixed at the various time points indicated in Results and then immunostained according to previously published procedures (Kuang et al., 2006). In brief, fixative solution consisting of 4% paraformaldehyde-PBS was added to the myofibers for 10 min at RT and then washed with 100 mM glycine-PBS to stop the fixation. Afterward, the myofibers were washed three times with PBS, placed into blocking solution (0.2% Triton X-100–PBS with 1% BSA, 0.1% Azide, and 5% goat serum) containing the primary antibody, and then stored overnight at 4°C. After this, the myofibers were washed three times in PBS and then incubated with the appropriate secondary antibody at a dilution of 1:3,500 or 1:1,000 for Alexa Fluor 594 and 488, respectively.
Microscope and image capture
Fluorescence and phase-contrast images of cells or myofibers in PBS were acquired using an inverted microscope (DMI 4000B; Leica) with accompanying dye set filters and 20× NA 0.40 or 40× NA 0.55 objectives at RT. Images were digitally captured using a cooled color 12-bit camera (Retiga 2000R Fast 1394; QImaging) with QCapture Pro software (version 6.0; QImaging). Images were optimized for color balance, brightness, and contrast using Photoshop CS3 (Adobe Systems, Inc.) and then assembled into figures using Canvas X (ACD Systems, Inc.).
ChIP analysis was performed as previously described (Parker et al., 2006) but with modifications. Primary mouse myoblasts, C2C12 myoblasts, or myotubes were cross-linked with 1% formaldehyde for 10 min, and afterward, the cells were harvested, washed with cold PBS, and resuspended in nuclear SDS lysis buffer containing 1% SDS, 10 mM EDTA, 50 mM Tris, pH 8.1, and 1× Complete antiprotease cocktail (Roche). The lysate was then sonicated by Bioruptor (Diagenode Inc.) under conditions that consistently yielded DNA fragment sizes of 100–400 bp. Sonicated chromatin was clarified and then diluted 10-fold in immunoprecipitation buffer (16.7 mM Tris, pH 8.0, 1.2 mM EDTA, 167 mM NaCl, 1.1% Triton X-100, and 0.01% SDS) to bring the final concentration of SDS to 0.1%. ChIP reactions were performed overnight at 4°C with 50 µg chromatin and 1–2 µg of specific antibodies. Afterward, the immunocomplexes were extensively washed, accordingly, and reverse cross-linked at 65°C overnight. DNA was recovered by phenol/chloroform, ethanol precipitated, and then quantitated by using a fluorospectrometer (ND-3300; NanoDrop Technologies). The DNA precipitates and input (0.05% of total chromatin used for the immunoprecipitation) were analyzed by semiquantitative PCR using corresponding primers for the indicated promoter. The sequences used were Cdc6-E1 (forward, 5′-TGATGAGTGACAACTAATCAG-3′; and reverse, 5′-GAGCTTTGCACTCTTCAGG-3′), Cdc6-E2 (forward, 5′-AGGTAACTGGCGATTGTGCT-3′; and reverse, 5′-GCTCTGGCTGTCTTGGAACT-3′), and Mcm2 (forward, 5′-CCTTCCGCTCTAGATTGACG-3′; and reverse, 5′-AGAGGAAGATACCGGCCAAG-3′). PCR was performed by using a PCR Master Mix kit (Roche) in a reaction volume of 25 µl consisting of 3.0 µl of precipitated DNA, 10 pmol of the appropriate primers, and 0.1 µCi α-[32P]dCTP in buffer. The thermal cycle program for amplification of the Cdc6 promoter sequence was 94°C for 3 min, followed by 29 cycles of 94°C for 15 s, 54°C for 30 s, and then 72°C for 30 s. PCR products were resolved on 8% native polyacrylamide gels and visualized by autoradiography.
Total RNA was prepared using the TRIZOL reagent (Invitrogen) accordingly. cDNA was generated by using the First-Strand cDNA Synthesis kit (GE Healthcare), and this was then amplified by PCR using specific primers spanning at least two exon regions of Cdc6, MyoD, or GAPDH. Quantification of GAPDH levels in the same cDNA samples measured in separate PCR reactions served as an endogenous control. Each product was resolved by agarose gel electrophoresis and visualized by ethidium bromide staining.
Online supplemental material
Fig. S1 shows that MyoD can occupy the Mcm2 promoter in myoblasts, and reporter assays show that the regulatory region of Cdc6 is responsive to MyoD, E2F3a, or Myf5 in C3H10T1/2 cells. Fig. S2 shows the conversion of C2C12 myoblasts to a quiescent state, the analysis of Myf5 and E2F3a expression in serum-stimulated quiescent myoblasts, the colocalization of MyoD and Cdc6 in activated satellite cells in association with myofibers, and the expression of Myf5 in quiescent myoblasts depleted of MyoD after serum stimulation.
We thank Michael A. Rudnicki for providing primary mouse myoblasts and Margaret Buckingham and David Samols for careful reading of the manuscript.
The project described was supported by grant R01AR49258 from the National Institutes of Health and the National Institute of Arthritis and Musculoskeletal and Skin Diseases to M.L. Harter.